Re: Farmas USA
BBP offers a different approach to biotech investing by handpicking only firms that have attained FDA approval for their leading drug. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. BBP is likely to tilt smaller than our neutral cap-weighted benchmark because the fund equal-weights its holdings, and it dips into micro-caps as well. Unsurprisingly, risk is elevated compared to our benchmark. BBP can be tricky to trade at any scale. Onscreen volume is thin and spreads are large, while the small-cap basket may cause some liquidity problems for larger investors. It also charges a very high expense ratio for this segment. Overall, BBP provides an alternative but pricey take on the biotech segment.
BBP/Semanal
BBC / semanal